SBIR/STTR Research Award

CHITOSAN-ZINC AS AN IMMUNOLOGICAL ADJUVANT

Award identifier f35be2a24b59d9ac8e2fce0e0201e2e88b638d87c7691fe64a1d1d63885b9989Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$98,625

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ZONAGEN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

An effective immunological adjuvant is one that is able to enhance both antibody and cell mediated immune responses. Alum is the only adjuvant widely licensed for human use and is reported as stimulating effective T-helper cell type 2 (Th-2) like responses. Th-2 responses are typified by production of predominately IgG1, IgE and the cytokines IL-4, IL-5, IL-6 and IL-10. In contrast adjuvants such as Complete Freund?s adjuvant, stimulate strong antibody responses with a preponderance of IgG2a. This type of response is indicative of a Th-1 response and is associated with the presence of cell mediated immunity, delayed type hypersensitivity, induction of complement fixing and IgA antibodies and the cytokines IFN-gamma, IL-2 and IL-12. Desired adjuvants, especially for poorly immunogenic, subunit, recombinant protein and synthetic peptide and carbohydrate antigens, are those capable of stimulating Th-1 immune responses. In this study we will characterize the cytokine and specific antibody response using a new adjuvant developed at Zonagen. We believe this adjuvant, which was developed to combine the unique immune modulating properties of chitosan and zinc, will have several advantages in the preparation of vaccines. PROPOSED COMMERCIAL APPLICATION: Products, such as improved adjuvants, that will enhance the immune response to poorly immunogenic antigens, should be widely received and commercially profitable.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.